Molecular diagnostics firm Nanosphere believes the results of a new multicenter study that assessed the performance of its Verigene Gram-Positive Blood Culture Test could lead to broader clinical adoption, according to a company spokesperson.
Lindsay Saxon told BioArray News this week that the results of the study, published recently in the journal PloS Medicine, are "significant" as they "further validate the compelling value" of the test.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.